Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06113445 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
A Phase 3 study of Non-segmental Vitiligo, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
- 20
- Study locations
NCT06113445: Active Phase 3 study of Non-segmental Vitiligo, sponsored by Incyte Corporation.
NCT06113445 is a Phase 3 study of Non-segmental Vitiligo that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 467 participants, above the 218-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06113445, a Phase 3 study of Non-segmental Vitiligo, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Primary Outcome
≥75% improvement in facial Vitiligo Area Scoring Index.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Povorcitinib
Study Locations (20)
Florida
- Renaissance Research - Cape Coral
- Encore Medical Research, Llc - Hollywood
- Savin Medical Group, Rc - Miami
- Skin Research of South Florida, Llc - Miami
- San Marcus Research Clinic Inc. - Miami Lakes
- Olympian Clinical Research - Tampa
- Forcare Clinical Research - Tampa
California
- University of California Irvine - Irvine
- Clinical Science Institute Clinical Research Specialists Inc - Santa Monica
- Cura Clinical Research - Sherman Oaks
- Sutter Health Palo Alto Medical Foundation Pamf Sunnyvale Center - Sunnyvale
Georgia
- Cleaver Medical Group - Cumming
- Dermatology and Surgery Specialists of North Atlanta - Marietta
- Pivotal Research Solutions - Stonecrest
Massachusetts
- Allcutis Research, Llc - Beverly
- Metro Boston Clinical Partners - Brighton
Michigan
- Great Lakes Research Group Inc - Bay City
- Wayne State University Physician Group Dermatology - Dearborn
Alabama
- Cahaba Dermatology - Hoover
Indiana
- Options Research Group, Llc - Kokomo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2027-02-24 |
| Phase | Phase 3 |
What the registry record for NCT06113445 still lists
NCT06113445 is an interventional study that assigns participants to a tested intervention. The registered 467 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (114% higher).
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06113445 names 20 study sites across 7 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06113445 about?
NCT06113445 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)". This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
What is the current status of trial NCT06113445?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2023-11-29. Estimated completion is 2027-02-24.
What conditions does trial NCT06113445 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT06113445?
The interventions under investigation include: Placebo (DRUG), Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06113445?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06113445 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06113445's enrollment target sits among peer trials
467 1st of 9 higher than 9 of 9 other Non-segmental Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-segmental Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
ACTIVE NOT RECRUITING · Phase 3
-
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
COMPLETED · Phase 3
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06456554 · 467 participants · NA
Acellular Dermal Matrix Investigation in Breast Reconstruction
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI